- Home
- NHS vs SERA Comparison
NHS vs SERA Comparison
Compare NHS & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- SERA
- Stock Information
- Founded
- NHS 2003
- SERA 2008
- Country
- NHS United States
- SERA United States
- Employees
- NHS N/A
- SERA N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- SERA Precision Instruments
- Sector
- NHS Finance
- SERA Health Care
- Exchange
- NHS Nasdaq
- SERA Nasdaq
- Market Cap
- NHS 230.5M
- SERA 208.7M
- IPO Year
- NHS N/A
- SERA 2021
- Fundamental
- Price
- NHS $7.54
- SERA $8.35
- Analyst Decision
- NHS
- SERA
- Analyst Count
- NHS 0
- SERA 0
- Target Price
- NHS N/A
- SERA N/A
- AVG Volume (30 Days)
- NHS 111.8K
- SERA 87.5K
- Earning Date
- NHS 01-01-0001
- SERA 11-06-2024
- Dividend Yield
- NHS 13.44%
- SERA N/A
- EPS Growth
- NHS N/A
- SERA N/A
- EPS
- NHS N/A
- SERA N/A
- Revenue
- NHS N/A
- SERA $94,000.00
- Revenue This Year
- NHS N/A
- SERA N/A
- Revenue Next Year
- NHS N/A
- SERA $4,471.43
- P/E Ratio
- NHS N/A
- SERA N/A
- Revenue Growth
- NHS N/A
- SERA N/A
- 52 Week Low
- NHS $6.95
- SERA $4.90
- 52 Week High
- NHS $9.17
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- NHS 25.88
- SERA 57.84
- Support Level
- NHS $7.74
- SERA $7.91
- Resistance Level
- NHS $7.93
- SERA $8.60
- Average True Range (ATR)
- NHS 0.06
- SERA 0.58
- MACD
- NHS -0.02
- SERA 0.07
- Stochastic Oscillator
- NHS 2.25
- SERA 67.96
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.